BMEA (Biomea Fusion) OCF Margin %: 0.00% (As of Mar. 2026)


BMEA Biomea Fusion Inc BMEA
31 GF Score
Price $1.23
! 1 Warning Sign
View Full Analysis

What is Biomea Fusion OCF Margin %?

Biomea Fusion BMEA -1.60% 31 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates BMEA with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Biomea Fusion ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Biomea Fusion's Cash Flow from Operations for the three months ended in Mar. 2026 was $-11.67 Mil. Biomea Fusion's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Biomea Fusion's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Biomea Fusion's current OCF Yield % is -63.39%.

The historical rank and industry rank for Biomea Fusion's OCF Margin % or its related term are showing as below:


BMEA's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Biomea Fusion OCF Margin % Related Terms

Biomea Fusion OCF Margin % Historical Data

* Premium members only.

The historical data trend for Biomea Fusion's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomea Fusion OCF Margin % Chart

Biomea Fusion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Biomea Fusion Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BMEA
31GF Score
Biomea Fusion Inc BMEA
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomea Fusion OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Biomea Fusion's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-70.371/0
= %

Biomea Fusion's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-11.669/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Biomea Fusion (BMEA) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Biomea Fusion and its competitors. According to the industry distribution chart, Biomea Fusion ranks #999999 out of 959 companies in the Biotechnology industry.
Is Biomea Fusion's OCF Margin % too high?
Biomea Fusion's current OCF Margin % is 0.00%. Based on the distribution chart, Biomea Fusion ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biomea Fusion has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Biomea Fusion's OCF Margin % compare to VRCA and PMN?
According to the Biotechnology industry distribution chart, Biomea Fusion ranks #999999 out of 959 companies for OCF Margin %. This places Biomea Fusion in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Biomea Fusion and its competitors. Biomea Fusion's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomea Fusion stock overvalued right now?
Biomea Fusion (BMEA) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Biomea Fusion's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Biomea Fusion (BMEA), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomea Fusion Business Description

Address 1599 Industrial Road, San Carlos, CA, USA, 94070
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
31GF Score

Get the complete analysis for BMEA

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.23
Price